Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial. Lancet (London, England) Sarraj, A., Abraham, M. G., Hassan, A. E., Blackburn, S., Kasner, S. E., Ortega-Gutierrez, S., Hussain, M. S., Chen, M., Johns, H., Churilov, L., Pujara, D. K., Shaker, F., Maali, L., Cardona Portela, P., Herial, N. A., Gibson, D., Kozak, O., Arenillas, J. F., Yan, B., Pérez de la Ossa, N., Sundararajan, S., Hu, Y. C., Cordato, D. J., Manning, N. W., Hanel, R. A., Aghaebrahim, A. N., Budzik, R. F., Hicks, W. J., Blasco, J., Wu, T. Y., Tsai, J. P., Schaafsma, J. D., Gandhi, C. D., Al-Mufti, F., Sangha, N., Warach, S., Kleinig, T. J., Yogendrakumar, V., Ng, F., Samaniego, E. A., Abdulrazzak, M. A., Parsons, M. W., Rahbar, M. H., Nguyen, T. N., Fifi, J. T., Mendes Pereira, V., Lansberg, M. G., Albers, G. W., Furlan, A. J., Jabbour, P., Sitton, C. W., Sila, C., Bambakidis, N., Davis, S. M., Wechsler, L., Hill, M. D., Grotta, J. C., Ribo, M., Campbell, B. C. 2024

Abstract

Multiple randomised trials have shown efficacy and safety of endovascular thrombectomy in patients with large ischaemic stroke. The aim of this study was to evaluate long-term (ie, at 1 year) evidence of benefit of thrombectomy for these patients.SELECT2 was a phase 3, open-label, international, randomised controlled trial with blinded endpoint assessment, conducted at 31 hospitals in the USA, Canada, Spain, Switzerland, Australia, and New Zealand. Patients aged 18-85 years with ischaemic stroke due to proximal occlusion of the internal carotid artery or of the first segment of the middle cerebral artery, showing large ischaemic core on non-contrast CT (Alberta Stroke Program Early Computed Tomographic Score of 3-5 [range 0-10, with lower values indicating larger infarctions]) or measuring 50 mL or more on CT perfusion and MRI, were randomly assigned, within 24 h of ischaemic stroke onset, to thrombectomy plus medical care or to medical care alone. The primary outcome for this analysis was the ordinal modified Rankin Scale (range 0-6, with higher scores indicating greater disability) at 1-year follow-up in an intention-to-treat population. The trial is registered at ClinicalTrials.gov (NCT03876457) and is completed.The trial was terminated early for efficacy at the 90-day follow-up after 352 patients had been randomly assigned (178 to thrombectomy and 174 to medical care only) between Oct 11, 2019, and Sept 9, 2022. Thrombectomy significantly improved the 1-year modified Rankin Scale score distribution versus medical care alone (Wilcoxon-Mann-Whitney probability of superiority 0·59 [95% CI 0·53-0·64]; p=0·0019; generalised odds ratio 1·43 [95% CI 1·14-1·78]). At the 1-year follow-up, 77 (45%) of 170 patients receiving thrombectomy had died, compared with 83 (52%) of 159 patients receiving medical care only (1-year mortality relative risk 0·89 [95% CI 0·71-1·11]).In patients with ischaemic stroke due to a proximal occlusion and large core, thrombectomy plus medical care provided a significant functional outcome benefit compared with medical care alone at 1-year follow-up.Stryker Neurovascular.

View details for DOI 10.1016/S0140-6736(24)00050-3

View details for PubMedID 38346442